Xencor Inc

Затворен

СекторЗдравеопазване

23.21 1.49

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.48

Максимум

23.41

Ключови измерители

By Trading Economics

Приходи

-22M

-151M

Продажби

47M

51M

EPS

-0.29

Марж на печалбата

-294.108

Служители

260

EBITDA

109M

-12M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+31.75% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

166M

1.6B

Предишно отваряне

21.72

Предишно затваряне

23.21

Xencor Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 19:16 ч. UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

13.08.2026 г., 19:21 ч. UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

12.08.2026 г., 19:56 ч. UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

11.08.2026 г., 19:26 ч. UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

10.08.2026 г., 19:31 ч. UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

7.08.2026 г., 23:16 ч. UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

6.08.2026 г., 20:03 ч. UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

3.08.2026 г., 19:51 ч. UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

31.07.2026 г., 20:03 ч. UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

30.07.2026 г., 19:03 ч. UTC

News
Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

29.07.2026 г., 19:36 ч. UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

28.07.2026 г., 20:07 ч. UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

27.07.2026 г., 19:11 ч. UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

24.07.2026 г., 19:11 ч. UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22.07.2026 г., 20:06 ч. UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21.07.2026 г., 19:02 ч. UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20.07.2026 г., 19:41 ч. UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Сравнение с други в отрасъла

Ценова промяна

Xencor Inc Прогноза

Ценова цел

By TipRanks

31.75% нагоре

12-месечна прогноза

Среден 30.29 USD  31.75%

Висок 44 USD

Нисък 20 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Xencor Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

9

Купи

1

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat